Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product.

Dendritic cells (DCs) transfected with mRNA encoding human telomerase reverse transcriptase (hTERT) have been shown to represent potent inducers of CTLs and antitumor immunity. However, it has become widely accepted that not only CTLs but also CD4(+) T helper cells are critical to the generation, as well as to the maintenance, of potent antitumor responses in vivo. In this study, we sought to determine whether human DCs transfected with mRNA encoding a chimeric hTERT/lysosome-associated membrane protein (LAMP-1) protein, carrying the endosomal/lysosomal sorting signal of the LAMP-1, are capable of stimulating concomitant hTERT-specific CD8(+) and CD4(+) T-cell responses in vitro. We show that processing of hTERT/LAMP-1 transcripts leads to enhanced stimulation of hTERT-specific CD4(+) T cells and does not negatively affect intracellular generation and subsequent presentation of MHC class I epitopes, hence, generating a CTL response. These findings provide a preclinical rationale of using DCs transfected with the chimeric hTERT/LAMP-1 RNA in vaccine trials to facilitate generation of antigen-specific CD4(+) T-cell responses that may be required to stimulate and maintain an optimal CD8(+) CTL response in vivo.

[1]  E. Gilboa,et al.  Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. , 2002, The Journal of clinical investigation.

[2]  B. Armbruster,et al.  N-Terminal Domains of the Human Telomerase Catalytic Subunit Required for Enzyme Activity in Vivo , 2001, Molecular and Cellular Biology.

[3]  Michel C. Nussenzweig,et al.  Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.

[4]  A. Khanolkar,et al.  Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells. , 2001, Virology.

[5]  E. Blackburn,et al.  A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Steinman,et al.  Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. , 2001, The Mount Sinai journal of medicine, New York.

[7]  P. Dahm,et al.  Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. , 2001, Cancer research.

[8]  M. Björkholm,et al.  Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity. , 2001, Clinical chemistry.

[9]  D. Schendel,et al.  The generation of LMP2a‐specific cytotoxic T lymphocytes for the treatment of patients with Epstein‐Barr virus‐positive Hodgkin disease , 2001, European journal of immunology.

[10]  D. Weissman,et al.  HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response1 , 2000, The Journal of Immunology.

[11]  Eli Gilboa,et al.  Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. , 2000, Nature Medicine.

[12]  K. Rock,et al.  Characterization of MHC class II‐presented peptides generated from an antigen targeted to different endocytic compartments , 2000, European journal of immunology.

[13]  E. Gilboa,et al.  Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. , 2000, Cancer research.

[14]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[15]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[16]  J. Shay,et al.  Telomerase in cancer: diagnostic, prognostic, and therapeutic implications. , 1998, The cancer journal from Scientific American.

[17]  E. Gilboa,et al.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.

[18]  C. Melief,et al.  Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.

[19]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[20]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[21]  R. Siliciano,et al.  The Enhanced Immune Response to the HIV gp160/LAMP Chimeric Gene Product Targeted to the Lysosome Membrane Protein Trafficking Pathway* , 1997, The Journal of Biological Chemistry.

[22]  R. Germain,et al.  Processing and Presentation of Endocytically Acquired Protein Antigens by MHC Class II and Class I Molecules , 1996, Immunological reviews.

[23]  Kathleen R. Cho,et al.  Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Siliciano,et al.  Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. , 1995, Journal of immunology.

[25]  M. Bunce,et al.  Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. , 1995, Tissue antigens.

[26]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[27]  R. Schreiber,et al.  Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.

[28]  C. Peters,et al.  Targeting of a lysosomal membrane protein: a tyrosine‐containing endocytosis signal in the cytoplasmic tail of lysosomal acid phosphatase is necessary and sufficient for targeting to lysosomes. , 1990, The EMBO journal.

[29]  K. von Figura,et al.  The tyrosine motifs of Lamp 1 and LAP determine their direct and indirect targetting to lysosomes. , 2002, Journal of cell science.

[30]  T. Wu,et al.  Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene , 2001, Gene Therapy.

[31]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.